Investor Relations

Company Overview

MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.

Stock Information

IR Contacts


MAIA Biotechnology, Inc.
444 West Lake Street
Suite 1700
Chicago, IL 60606
T: 312-416-8592

Investor Inquiries

MAIA Biotechnology
Joseph McGuire
Chief Financial Officer

Investor Relations

Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.